Skip to main content
Contact
Login
Our Company
Our Company
Mission
Leadership
Clinical Studies
Clinical Studies
ECLIPSE
GRECO-Breast Cancer
Solutions
Solutions
Treatment Selection
Residual Disease & Recurrence Monitoring
Early Detection
Biopharma Solutions
International
Investors
Investors
Media
Media
Press Releases
Resources and Media Assets
Contacts
Careers
Careers
Join Our Mission
Jobs
Press Releases
Investors Menu
Home
Press Releases
Events & Presentations
Events
Presentations
Stock Information
Stock Quote & Chart
Analyst Coverage
Financials
Quarterly Results
Annual Reports
SEC Filings
Corporate Governance
Governance Documents
Leadership
Board of Directors
Committee Composition
Resources
Investor FAQs
Investor Email Alerts
Investor Contacts
Normal
Press Release RSS Feed (opens in new window)
Press release year list
2023
2022
2021
2020
2019
2018
2017
December 30, 2019
Guardant Health to Present at the 38th Annual J.P. Morgan Healthcare Conference
December 19, 2019
Guardant Health Receives Expanded Medicare Coverage for Guardant360 Across the Vast Majority of Solid Tumor Cancers
December 13, 2019
Large-Scale Study Shows Guardant360 Effectively Guides Precision Oncology Treatment in Metastatic Breast Cancer Patients
December 11, 2019
Study Shows Only 40 Percent of Patients with Metastatic Colon Cancer Receive Guideline-Recommended Biomarker Testing
November 7, 2019
Guardant Health Reports Third Quarter 2019 Financial Results and Raises 2019 Revenue Guidance
November 4, 2019
Guardant Health to Report Third Quarter 2019 Financial Results on November 7, 2019
October 23, 2019
Guardant Health Initiates ECLIPSE Pivotal Study for its LUNAR-2 Blood Test for Colorectal Cancer Screening
September 28, 2019
Data Presented at ESMO Show Metastatic CRC Patients with HER2 Amplification Detected by Guardant360 Experience Clinical Benefit After Targeted Therapy
August 6, 2019
Guardant Health Reports Second Quarter 2019 Financial Results and Raises 2019 Revenue Guidance
August 5, 2019
Largest Study of its Kind Finds Guardant360 MSI Highly Concordant to Tissue
August 1, 2019
Guardant Health to Participate in Upcoming Investor Conferences
August 1, 2019
Guardant Health to Report Second Quarter 2019 Financial Results on August 6, 2019
May 29, 2019
Guardant Health to Present at the William Blair 2019 Growth Stock Conference
May 23, 2019
Guardant Health Announces Pricing of Public Offering of Common Stock
May 20, 2019
Guardant Health, Inc. Announces Proposed Public Offering of Common Stock
May 15, 2019
Guardant Health to Present Precision Oncology Data Across the Continuum of Care at the ASCO Annual Meeting
May 9, 2019
Guardant Health Reports First Quarter 2019 Financial Results and Raises 2019 Revenue Guidance
May 3, 2019
Guardant Health to Present at the Bank of America Merrill Lynch 2019 Health Care Conference
May 2, 2019
Guardant Health to Report First Quarter 2019 Financial Results on May 9, 2019
April 23, 2019
Guardant Health Appoints Dr. Bahija Jallal to its Board of Directors
April 15, 2019
NILE Study Results Demonstrating Guardant360’s High Concordance to Tissue Testing in Advanced NSCLC Published in Clinical Cancer Research
April 9, 2019
Guardant Health Announces Commercial Payer Progress with more than 150 Million Lives Covered for Guardant360
March 28, 2019
Palmetto GBA issues Draft Local Coverage Determination Expanding Guardant360 Medicare Coverage to Most Solid Tumor Types
March 27, 2019
Guardant Health Announces Definitive Agreement to Acquire Bellwether Bio
March 12, 2019
Guardant Health Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Outlook
March 11, 2019
Guardant Health to Present at the 39th Annual Cowen Health Care Conference
March 11, 2019
Guardant Health to Report Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
February 27, 2019
Guardant360 Performance Matches Standard-of-Care Tissue Testing in First-Line, Advanced Non-Small Cell Lung Cancer, NILE Study Shows, Meeting Primary Endpoint
February 14, 2019
Guardant Health to Present at the 8th Annual Leerink Partners Global Healthcare Conference
January 7, 2019
Guardant Health Announces Launch of the LUNAR Assay for Detection of Early-Stage Cancer and Recurrence to Academic and Biopharmaceutical Researchers